Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
RedPath Integrated Pathology
company
About
RedPath Integrated Pathology is a reference laboratory that provides support services for oncology cases.
- 51 - 100
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $6.50M
- Industries
- Biotechnology,Health Care,Medical
- Founded date
- Jan 1, 2004
- Number Of Employee
- 51 - 100
- Operating Status
- Active
RedPath Integrated Pathology, LLC operates as a reference laboratory and provides support services for oncology cases. It offers PathFinderTG, a testing platform for resolving diagnoses from the original pathology specimen. The company serves pathologists, clinicians, and patients. RedPath Integrated Pathology, LLC was founded in 2004 and is headquartered in Pittsburgh, Pennsylvania.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$6.50M
RedPath Integrated Pathology has raised a total of
$6.50M
in funding over 2 rounds. Their latest funding was raised on
Dec 20, 2006 from a Series A round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Dec 20, 2006 | Series A | $6.50M | 2 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
2
RedPath Integrated Pathology is funded by 2 investors.
HMA Capital Partners
and Inflexion Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series A |
Inflexion Partners
|
— | Series A |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
